Phone: +1 (800) 783-7065 Email: information@cbd-international.net
CBD International

Supporting a loved one through cannabis-based cancer treatment

Supporting someone with cancer can feel like managing appointments, medication changes, fatigue, pain and family worries at the same time. If medicinal cannabis is being considered, your role may include helping organise products, tracking symptoms, attending consultations and providing calm, dependable care. The most helpful support is informed, respectful and centred on the patient’s comfort rather than assumptions about what will work.

Cannabis-based cancer treatment often refers to cannabinoid medicines used alongside conventional oncology care. Cannabis and CBD oils are not established cures for cancer, and their role is generally connected with symptom relief, comfort and quality of life. A treatment protocol should be individualised, legally arranged and reviewed by the treating team, especially when pain, nausea, poor appetite, anxiety or sleep problems are affecting daily life.

Understanding what cannabis-based treatment can do

Cannabis contains many active compounds, including THC and CBD, which produce different effects. THC may help with certain symptoms but can also cause intoxication, drowsiness and impaired concentration. CBD is generally associated with less psychoactive effect, although products vary widely and even a CBD-dominant preparation can cause side effects or interact with prescription medicines.

The main aims of a medicinal cannabis protocol are to ease specific symptoms and improve quality of life. Depending on the formulation and the person’s circumstances, a clinician may consider cannabis for pain, nausea, appetite loss, sleep disturbance or anxiety related to illness. Evidence differs for each symptom, so regular reviews and clear goals are essential. A protocol should state which symptom is being treated, how response will be measured and when the treatment should be reviewed.

Families can contribute useful observations without taking control away from the patient. Note changes in pain levels, sleep, meals, nausea, mood and daily function, while asking permission before recording private information. Those notes can help the oncology team distinguish a treatment effect from disease progression. They can also prevent someone from having to repeat the same details during a difficult appointment.

Working within Australia's healthcare system

In Australia, medicinal cannabis is regulated nationally through the Therapeutic Goods Administration and the Australian Register of Therapeutic Goods. Access generally involves an assessment by a qualified practitioner, product approval or access through the appropriate TGA pathway, and dispensing through a licensed pharmacy. A general practitioner may be able to prescribe lower-THC products, while higher-THC medicines commonly require assessment by a specialist.

State and territory rules can differ, particularly around approved products, dispensaries and how prescriptions are supplied. Many families in Sydney, Melbourne, Brisbane, Adelaide and Perth use a medicinal cannabis prescriber, often reached through telehealth, while people in regional and remote areas may have fewer local specialists and rely on online consultations and pharmacy delivery. A treating GP, oncologist or palliative-care service can help identify the lawful route that fits the patient’s location and needs.

Families who want a clearer overview can browse the product range before speaking with a practitioner, but product information should be treated as guidance rather than a personalised prescription. Medicare usually does not subsidise medicinal cannabis products themselves, so cost deserves an early discussion. Public hospital oncology and palliative-care services remain central to treatment, and Cancer Council Australia’s nurse line on 13 45 25 can offer additional support and guidance for people navigating care.

Comparing oils and administration methods

Cannabis oils may be CBD-dominant, THC-containing or balanced between the two. The active ingredients, concentration, carrier oils, flavouring and manufacturing standards can differ between products. Check the ingredient list, batch information, storage requirements and expiry date. A family should never transfer a product between containers or assume that similar-looking bottles contain the same formulation.

Oral products may be used for pain, nausea or other symptom management according to the prescribed protocol. Some oils are swallowed, while others are placed under the tongue for a limited time, depending on the formulation and directions. When comparing oral pain relief treatments, ask about onset, duration, food requirements, taste, swallowing difficulties and how the product should be stored. Onset can be gradual, so extra doses should never be added without advice.

Rectal cannabis preparations may be considered when oral use is difficult or when a local formulation is considered appropriate by the prescriber. They may provide another administration option for nausea, pain or discomfort, but dignity, privacy and the patient’s preferences should guide the discussion. Questions about leakage, irritation, storage, refrigeration and ease of use are practical and important.

Route of administration should follow the treatment plan rather than convenience alone. Keep the original packaging and instructions, use the product only as directed and ask the dispensing chemist or prescribing practitioner if the bottle, label or instructions are unclear. A personalised protocol is safer than advice borrowed from another patient, particularly when several pain medicines are being used.

Building a practical family care plan

A clear routine can reduce confusion for the patient and the household. Put medicines in one secure, labelled area and keep a current list of prescriptions, supplements and medicinal cannabis products. Record the prescribed product, administration time and the symptom being monitored. Use a simple daily scale, but avoid making every activity feel like a test or allowing numbers to replace the patient’s own preferences.

Before doses begin, agree on who will prepare or administer them, when the oncology team should be contacted and what happens if the person feels too drowsy or unwell. Discuss whether the patient wants help, prefers to manage the process independently or wants family members to step away. A plan that respects consent can make intimate, sensitive care feel safer.

Points to clarify with the treatment team

Ways family members can provide practical support

Review the plan after the first few days and again when treatment changes. What works for pain during one period may not suit nausea later in treatment. Regular communication with the oncology, palliative-care or prescribing team allows the protocol to be adjusted while keeping cannabis within the wider cancer care plan.

Watching for side effects and warning signs

Common effects can include drowsiness, dizziness, dry mouth, altered appetite, abdominal discomfort, anxiety or confusion. THC-containing products may also affect perception, memory and reaction time. Older adults, people with reduced mobility and those taking sedating medicines may be more sensitive, so the initial response should be monitored carefully. Avoid increasing the dose or frequency to overcome a slow effect.

Cannabinoids can interact with several medicines, including opioid painkillers, sedatives, anticoagulants and some medicines used during cancer treatment. The oncology team and a pharmacist should review the full medication list, including supplements and non-prescription products. Cannabis should not be used to manage a new symptom until the team has considered whether it could be caused by the cancer, dehydration, infection, medication effects or another urgent problem.

Severe confusion, hallucinations, repeated vomiting, breathing difficulty, chest pain, fainting or a serious allergic reaction require prompt medical help. Call 000 for an emergency. For non-emergency concerns, contact the treating service, local GP or a pharmacist; Poison Information Centre advice is also available on 13 11 26. Australia’s driving and workplace rules vary by state and territory, and THC may remain detectable after its psychoactive effects have passed, so the patient should avoid driving until a qualified health professional advises otherwise.

Red flags should not automatically be attributed to cannabis. Increasing pain, new weakness, persistent nausea or reduced fluid intake may signal disease progression or another complication. Keep the oncology team informed even when a symptom seems minor, because that information can guide safer, faster decisions.

Taking the next step with a clear plan

Privacy matters throughout cancer care. Ask how the patient’s details will be stored, who may speak to family members and what consent is required before information is shared. A useful starting point is to review their patient support approach, then discuss consultation, application review and ongoing communication directly with the service. Existing medical records and the complete medication list should accompany any cannabis assessment.

Choose supportive care that suits the person, not just the treatment. This may involve coordinating medicinal cannabis with oncology appointments, palliative care, nursing support, sleep management and practical household help. Families also need permission to step back when possible, accept that symptoms may fluctuate and seek support when caregiving becomes overwhelming. A clearly assigned contact person can help coordinate appointments without placing the entire responsibility on one family member.

When you are ready to proceed, begin by contacting the oncology or palliative-care team with the patient’s permission and documenting the symptom that needs attention. A supervised, legal cannabis protocol can then be considered through the appropriate Australian pathway, with products ordered only after the required prescription or approval. Review its effectiveness, side effects and costs regularly, and keep every member of the care team informed as the patient’s needs change.